BD Diagnostics seeks US nod for superbug DNA test
This article was originally published in Clinica
Executive Summary
BD Diagnostics, a segment of Becton, Dickinson and Company, has filed with the US regulators a 510(k) application to market what it claims to be the first assay for the rapid and simultaneous identification of methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) in patients with positive blood cultures.